Drug
Trilaciclib clinical trials
Also written G1T28 and Cosela.
- studies test it
- 40
- open now
- 24
- in phase 3
- 7
- first study started
- 2015
Keep track of what changes. Save the trilaciclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
- G1T28
- 13
Studies by the year they started
40 studies that test it; most in 2024 (12)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2017 | 3 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 8 |
| 2024 | 12 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 30
- Phase 3
- 7
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 25
G1 Therapeutics, Inc. (10) · Jiangsu Simcere Pharmaceutical Co., Ltd. (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Sun Yat-sen University (3) · Pharmacosmos A/S (2) · Wake Forest University Health Sciences (1) · Borstkanker Onderzoek Groep (1) · Henan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Gemcitabine (2) · Carboplatin (2) · Cisplatin (2) · Pembrolizumab (1) · Etoposide (1) · Eribulin (1) · Tislelizumab (1) · Antineoplastic Agents (1)
Studies
Open first, then newest update. How each study uses trilaciclib is read from its arms, and is right about nine times in ten.
Testing it · 40
- Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerRecruitingPhase 3Pharmacosmos A/SNCT07473128Written as Trilaciclib
- Study of Trilaciclib and LurbinectidinRecruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT05578326Written as Trilaciclib
- Trilaciclib Combined With Immunochemotherapy for R/M HNSCCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07679997Written as Trilaciclib
- Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06992739Written as Trilaciclib and Sacituzumab Tirumotecan
- Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid TumorsRecruitingPhase 1Hebei Medical University Fourth HospitalNCT07490236Written as Trilaciclib group
- the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With TrilaciclibEnrolling by invitationPhase 2Henan Cancer HospitalNCT06370416Written as Trilaciclib
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07255612Written as Trilaciclib
- Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBCRecruitingPhase 2QIAO LINCT06955156Written as Trilaciclib
- A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.Not yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06364904Written as Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib
- Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCCRecruitingPhase 2Hunan Cancer HospitalNCT06752798Written as Trilaciclib + Cisplatin
- Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Shandong Cancer Hospital and InstituteNCT06714266Written as Trilaciclib
- Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of OsteosarcomaRecruitingPhase 2Peking University People's HospitalNCT06714383Written as Trilaciclib
- Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinRecruitingPhase 2Shanghai Chest HospitalNCT06698965Written as Trilaciclib
- Trilaciclib Prevents Myelosuppression With ChemoradiotherapyRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06490081Written as Trilaciclib
- Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal CancerRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06569459Written as Trilaciclib Injection [Cosela]
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsRecruitingPhase 2Sun Yat-sen UniversityNCT06569485Written as Trilaciclib+R-CHOP
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal MetastasisRecruitingPhase 2Jiangsu Province Nanjing Brain HospitalNCT06332287Written as combination of Trilaciclib and Pemetrexed
- A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLCRecruitingPhase 2Taixing People's HospitalNCT06328049Written as Trilaciclib Injection
- Myeloprotection With Trilaciclib in Pan-cancer PopulationNot yet recruitingPhase 2Sun Yat-sen UniversityNCT06297811Written as Trilaciclib Injection
- A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06151262Written as Trilaciclib+mFOLFIRINOX
See all 40 studies that test trilaciclib →
Given in every arm · 2 — trilaciclib is usual care beside what is tested
- A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using TrilaciclibRecruitingPhase 2Fudan UniversityNCT06699472Written as Trilaciclib Injection [Cosela]
- Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant ChemotherapyRecruitingPhase 2wang shusenNCT05978648Written as Trilaciclib
Codes
What other systems call trilaciclib · ClinicalTrials.gg INT001357
- MeSH (NLM) C000708352trilaciclibOne source NLM
- UNII (FDA) U6072DO9XGTRILACICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 2479690One source FDA
- Wikidata Q105592965trilaciclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C123281TrilaciclibOne source FDA
- DrugBank DB15442One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708352 | trilaciclib | One source NLM |
| UNII (FDA) | U6072DO9XG | TRILACICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2479690 | — | One source FDA |
| Wikidata | Q105592965 | trilaciclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C123281 | Trilaciclib | One source FDA |
| DrugBank | DB15442 | — | One source Wikidata |
Also registered as trilaciclib dihydrochloride (UNII 4BX07W725T · RxNorm 2479691).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.